Advanced wound care and regenerative medicine devices
Strategic Profile
In Q1 2026, SANUWAVE reported revenue of $9.6 million, up 3.1% year-over-year and the highest Q1 in company history, with 2026 full-year guidance of $51.0–$55.0 million (16–25% growth). The company sold 97 UltraMist systems, with UltraMist consumables revenue rising 15% to $6.7 million, positioning SANUWAVE as a scaled, recurring-revenue wound care platform with FDA-cleared products and a diversified clinical portfolio spanning wound healing, orthopedic, aesthetic, and cardiac applications.
Cyborg Score Rationale
SANUWAVE demonstrates solid fundamentals: record Q1 2026 revenue ($9.6M), strong guidance acceleration (16–25% growth), high gross margins (77.3%), and an FDA-cleared wound care platform with recurring consumables revenue. However, the company remains in net loss territory ($1.4M in Q1 2026) and operates at modest scale, limiting it from strong-to-exceptional ratings.
Top Insights
Q1 2026 marked highest quarterly revenue ($9.6M) in company history, driven by 15% consumables growth and company guidance of 16–25% annual growth
August 2020 acquisition of Celularity's UltraMIST device and wound care biologic partnership broadened portfolio with complementary products (BIOVANCE®, Interfyl®) and expanded commercial team to 100 professionals
SANUWAVE's proprietary PACE (Pulsed Acoustic Cellular Expression) technology is being applied across wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions
High gross margins (77.3% in Q1 2026) reflect strong pricing power and consumables-driven business model; early profitability indicators with adjusted EBITDA of $1.1M in Q1 2026
Named Competitors
MiMedx Wound Care — Allograft tissue matrices and biologics for advanced wound care
Organogenesis Wound Care — Advanced wound care matrices and skin substitutes
Bioventus Devices — Orthobiologic and regenerative medicine devices
STAAR Surgical — Surgical devices for vision and wound care applications
Recent Developments
(May 2026) Q1 2026 earnings: $9.6M revenue (highest Q1 in company history), 3.1% YoY growth, 77.3% gross margin, 97 UltraMist systems sold
(May 2026) 2026 full-year guidance of $51.0–$55.0 million (16–25% growth); Q2 2026 guidance of $11.1–$11.6 million (10–15% growth)
(May 2026) UltraMist consumables revenue rose 15% to $6.7 million, representing 100% of total revenue in Q1 2026
Open the full interactive SANUWAVE Health, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.